<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676178</url>
  </required_header>
  <id_info>
    <org_study_id>PR200-101</org_study_id>
    <nct_id>NCT04676178</nct_id>
  </id_info>
  <brief_title>A Study of PRA023 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetics Study of PRA023 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prometheus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Prometheus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is randomized, double-blind, placebo-controlled, single and multiple ascending dose&#xD;
      study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA023&#xD;
      in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">September 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Incidence, severity, and causal relationship of TEAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Maximum concentration after single and multiple ascending doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Time to reach maximum concentration after single and multiple ascending doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Half life after single and multiple ascending doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Area under the curve after single and multiple ascending doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Incidence of anti-drug antibody after single and multiple ascending doses</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAD Cohorts 1-6 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single intravenous doses of PRA023 in a dose escalation format</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohorts 1-6 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive intravenous doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 1-5 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive three intravenous doses of PRA023, one dose every 2 weeks, in a dose escalation format</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 1-5 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive three intravenous doses of placebo, one dose every 2 weeks,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRA023</intervention_name>
    <description>PRA023</description>
    <arm_group_label>MAD Cohorts 1-5 Experimental Arm</arm_group_label>
    <arm_group_label>SAD Cohorts 1-6 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>MAD Cohorts 1-5 Placebo Arm</arm_group_label>
    <arm_group_label>SAD Cohorts 1-6 Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female (of non-childbearing potential only) between minimum adult legal age&#xD;
             (according to local laws for signing the informed consent document) and 55 years of&#xD;
             age.&#xD;
&#xD;
          -  Females must be of non-childbearing potential and must have undergone one of the&#xD;
             following sterilization procedures, and have official documentation, at least 6 months&#xD;
             prior to the first dose:&#xD;
&#xD;
               1. hysteroscopic sterilization;&#xD;
&#xD;
               2. bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
               3. hysterectomy;&#xD;
&#xD;
               4. bilateral oophorectomy, or;&#xD;
&#xD;
               5. be postmenopausal with amenorrhea for at least 1 year prior to the first dose and&#xD;
                  have FSH serum levels consistent with postmenopausal status as per investigator&#xD;
                  judgment.&#xD;
&#xD;
          -  Male subjects must use reliable forms of contraception during sexual intercourse with&#xD;
             female partners from screening to 30 days after the end of dosing.&#xD;
&#xD;
          -  Good general health as determined by medical history, and by results of physical&#xD;
             examination, chest x-ray, vital signs, ECG, and clinical laboratory tests obtained&#xD;
             within 28 days (4 weeks) prior to study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of any clinically significant organ system disease that could&#xD;
             interfere with the objectives of the study or the safety of the subjects.&#xD;
&#xD;
          -  Blood pressure and heart rate are outside the ranges 90-140 mmHg systolic, 60-90 mmHg&#xD;
             diastolic, heart rate 60-100 beats/min.&#xD;
&#xD;
          -  12-lead ECG with any abnormality judged by the Investigator to be clinically&#xD;
             significant, QRS &gt;= 120 milliseconds (msec), or QTcF interval of &gt; 450 msec for men or&#xD;
             &gt;470 msec for women.&#xD;
&#xD;
          -  Presence or history of any abnormality or illness, which in the opinion of the&#xD;
             Investigator may affect absorption, distribution, metabolism or elimination of the&#xD;
             study drug.&#xD;
&#xD;
          -  Any screening laboratory evaluation outside the laboratory reference range that is&#xD;
             judged by the Investigator to be clinically significant.&#xD;
&#xD;
          -  History of or current active tuberculosis (TB) infection; history of latent TB that&#xD;
             has not been fully treated or current latent TB infection as indicated by a positive&#xD;
             QuantiFERON-TB test.&#xD;
&#xD;
          -  History of significant allergy to any medication as judged by the Investigator.&#xD;
&#xD;
          -  History of alcohol or drug abuse within the past 24 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison Luo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Prometheus Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

